← Eichor
Condition: Advanced Ovarian Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Advanced Ovarian Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Phase 1 · 1 location(s) · Ascentage Pharma Group Inc. · NCT06687070Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
Phase 1 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT04778839Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Pr
Phase 1/Phase 2 · 4 location(s) · Imunon · NCT05739981A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Phase 1 · 15 location(s) · OnCusp Therapeutics, Inc. · NCT06234423Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
Phase 3 · 11 location(s) · Women's Hospital School Of Medicine Zhejiang University · NCT05737303Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1 · 2 location(s) · Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · NCT07156253Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cance
Phase 2 · 1 location(s) · Bai-Rong Xia · NCT07125391HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT06769425Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo
Phase 3 · 8 location(s) · Imunon · NCT06915025Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
Phase 2 · 1 location(s) · Qilu Hospital of Shandong University · NCT06735326BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Phase 1/Phase 2 · 25 location(s) · BioInvent International AB · NCT04752826A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Phase 2 · 16 location(s) · MacroGenics · NCT06730347Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1 · 2 location(s) · Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · NCT06666270A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06215950Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer
Phase 2 · 1 location(s) · Institut du Cancer de Montpellier - Val d'Aurelle · NCT04282356No-Stoma Policy in Advanced Ovarian Cancer Surgery
NA · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT07213193A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Phase 1/Phase 2 · 1 location(s) · Jacobio Pharmaceuticals Co., Ltd. · NCT04686682This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497Ovarian Cancer Radiomics Approach in CT Led Evaluation
Phase N/A · 1 location(s) · Imperial College Healthcare NHS Trust · NCT06817174A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Su
Phase 1 · 1 location(s) · Boryung Pharmaceutical Co., Ltd · NCT07069335BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Phase 1 · 4 location(s) · Bio-Path Holdings, Inc. · NCT04196257Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Can
EARLY_Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT07144826WellSpan-THRIVE Cancer QOL Study
Phase N/A · 5 location(s) · WellSpan Health · NCT07433660At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT05740956Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanc
Phase 1 · 12 location(s) · Whitehawk Therapeutics, Inc. · NCT07444814Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 · 10 location(s) · Nammi Therapeutics Inc · NCT06582017The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer
NA · 2 location(s) · University of Colorado, Boulder · NCT07636200
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.